Skip to main content

Table 3 Proportion of patients stratified by treatment group (“concomitant LABA and ICS users”, “Switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the years 2004 to 2008

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

 

Year

 

2004

2005

2006

2007

2008

Concomitant LABA and ICS users

123,873 (52.0%)

152,857 (54.6%)

152,418 (53.3%)

172,225 (55.3%)

177,159 (57.6%)

Switchers

12,785 (5.4%)

13,266 (4.7%)

14,207 (5.0%)

14,446 (4.6%)

14,899 (4.8%)

Non-concomitant LABA and ICS users

1,314 (0.6%)

1,686 (0.6%)

1,992 (0.7%)

1,896 (0.6%)

1,936 (0.6%)

LABA users without ICS

15,612 (6.5%)

19,200 (6.9%)

18,193 (6.4%)

17,810 (5.7%)

16,749 (5.4%)

ICS users without LABA

84,818 (35.6%)

92,970 (33.2%)

99,334 (34.7%)

105,252 (33.8%)

96,615 (31.4%)